Brand Guides
GLP-1 Brand Guide: Every Major Medication Explained
Complete, evidence-based guides for Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza, and Trulicity — covering dosing, side effects, costs, and how they compare.
⚠️ Medical Disclaimer
This page is for educational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs. Discuss all treatment decisions with a licensed healthcare provider who knows your complete medical history. Individual results vary significantly from clinical trial averages.
Novo Nordisk
Ozempic
Semaglutide — T2D primary; weight secondarily
Ozempic (semaglutide) is a once-weekly injectable GLP-1 receptor agonist manufactured by Novo Nordisk, FDA-approved in December 2017 for adults with type 2 diab...
Read complete guide →
Novo Nordisk
Wegovy
Semaglutide — Obesity / chronic weight management
Wegovy (semaglutide 2.4 mg) is a once-weekly injectable GLP-1 receptor agonist approved by the FDA in June 2021 specifically for chronic weight management. It r...
Read complete guide →
Novo Nordisk
Rybelsus
Semaglutide (oral) — T2D oral
Rybelsus is the world's first oral GLP-1 receptor agonist, containing semaglutide in a tablet formulation. Approved by the FDA in September 2019, Rybelsus makes...
Read complete guide →
Eli Lilly
Mounjaro
Tirzepatide — T2D primary
Mounjaro (tirzepatide) is a novel once-weekly injectable medication that is the first FDA-approved dual GIP/GLP-1 receptor agonist. Approved in May 2022 for typ...
Read complete guide →
Eli Lilly
Zepbound
Tirzepatide — Obesity / chronic weight management
Zepbound (tirzepatide) is a once-weekly injectable dual GIP/GLP-1 receptor agonist, FDA-approved in November 2023 for chronic weight management. It is the same ...
Read complete guide →
Novo Nordisk
Saxenda
Liraglutide — Obesity / chronic weight management
Saxenda (liraglutide 3.0 mg) is a once-daily injectable GLP-1 receptor agonist approved by the FDA in December 2014 for chronic weight management. It was the fi...
Read complete guide →
Novo Nordisk
Victoza
Liraglutide — T2D primary; CVD secondary
Victoza (liraglutide 1.8 mg) is a once-daily injectable GLP-1 receptor agonist approved by the FDA in January 2010 for type 2 diabetes management. It was one of...
Read complete guide →
Eli Lilly
Trulicity
Dulaglutide — T2D primary; CVD secondary
Trulicity (dulaglutide) is a once-weekly injectable GLP-1 receptor agonist manufactured by Eli Lilly, FDA-approved in September 2014 for type 2 diabetes. Trulic...
Read complete guide →
Compare Brands Side-by-Side
See how each brand stacks up against the others across weight loss, cost, side effects, and eligibility.
View All Brand Comparisons →📈 Calculate Your Projected Weight Loss
Use our evidence-based calculator to estimate outcomes for any GLP-1 medication.
Open Weight Loss Projector →